<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04312568</url>
  </required_header>
  <id_info>
    <org_study_id>5849-CPK-1001</org_study_id>
    <nct_id>NCT04312568</nct_id>
  </id_info>
  <brief_title>Evaluate Safety, Tolerability and Pharmacokinetics of Fadanafil （XZP-5849）in Chinese Healthy Adult Male Subjects</brief_title>
  <official_title>Evaluate Safety, Tolerability and Pharmacokinetics of Fadanafil （XZP-5849）in Chinese Healthy Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sihuan Pharmaceutical Holdings Group Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sihuan Pharmaceutical Holdings Group Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety , tolerability, and pharmacokinetics of
      ascending single dose Fadanafil （XZP-5849）in Chinese healthy adult male subjects. This is the
      first XZP-5849 clinical study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      XZP-5849 is a selective phosphodiesterase (PDE5) inhibitor. The proposed randomized Phase 1
      trial is a double-blind, placebo-controlled, single ascending dose study in approximately 66
      Chinese healthy adult male subjects. The study consists of 8 cohorts (1 cohort per dose
      level). Each subject will participate in only one cohort.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 10, 2018</start_date>
  <completion_date type="Actual">December 7, 2018</completion_date>
  <primary_completion_date type="Actual">December 7, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>8 dose groups within 12.5mg~500mg for single dose tolerability study to carrried out from low-dose group to high dose group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Electrocardiogram (ECG)</measure>
    <time_frame>Change from Baseline to 1, 2,4,6,8,12,24,36,46 hours after dosing.</time_frame>
    <description>To evaluate subject ECG Changing information</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter AUC(0-24)</measure>
    <time_frame>Pre dose and 0.25,0.5,0.75,1,1.5, 2, 2.5, 4, 6,8,12, 24,36 hours after Dosing</time_frame>
    <description>AUC(0-24) of Fadanafile is area under the curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Pressure and Heart Rate</measure>
    <time_frame>Change from Baseline to 1, 2,4,6,8,12,24,36,46 hours after dosing</time_frame>
    <description>To evaluate subject Blood Pressure and Heart Rate Changing information</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Healthy Subject</condition>
  <arm_group>
    <arm_group_label>Fadanafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 group: 12.5mg one dose; 25mg one dose; 50mg one dose; 100mg one dose; 200mg one dose; 300mg one dose; 400mg one dose; 500mg one dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>8 group: 12.5mg one dose; 25mg one dose; 50mg one dose; 100mg one dose; 200mg one dose; 300mg one dose; 400mg one dose; 500mg one dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fadanafil</intervention_name>
    <description>Dose escalation for 8 groups: 12.5mg one dose, 25mg one dose, 50mg one dose, 100mg one dose, 200mg one dose, 300mg one dose, 400mg one dose, 500mg one dose</description>
    <arm_group_label>Fadanafil</arm_group_label>
    <other_name>5849</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dose escalation for 8 groups: 12.5mg one dose, 25mg one dose, 50mg one dose, 100mg one dose, 200mg one dose, 300mg one dose, 400mg one dose, 500mg one dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects 18-45 years old, inclusive.

          -  Body weight ≥50kg and Body Mass Index: 19.0~25.0 kg/m2, inclusive

          -  subjects should be willing to take appropriate contraceptive measures during the
             period of taking the study drug and within 6 months after discontinuation to avoid
             pregnancy of their partners.

        Exclusion Criteria:

          -  Subjects who have a history of clinical significanct drug allergy (especially those
             who are known or suspected to have a history of allergy to any PDE-5 inhibitor or its
             components) or a history of atopic allergic diseases (asthma, urticaria, eczema
             dermatitis) or severe allergic constitution.

          -  History of clinically significant ECG abnormality or family history of long QT
             syndrome (grandparents, parents, brothers and sisters).

          -  Subjects with serious systemic diseases, such as respiratory, blood, endocrine,
             cardiovascular and cerebrovascular diseases or mental disorders.

          -  Subjects who have used over-the-counter drugs, health products, herbal medicine or
             traditional Chinese medicine within 2 weeks before screening, or are taking foods that
             affect CYP3A4, such as grapefruit or drinks containing grapefruit (except those who
             occasionally take paracetamol, but the total maximum dose cannot exceed 1g, and the
             drug is not allowed to take orally within 48 hours before the first administration).

          -  Subjects who have used any prescription drugs (especially CYP3A4 inhibitors, nitrates,
             α receptor blockers, drugs potential to cause QT interval prolongation, etc.) within 4
             weeks before screening.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haiyan Li, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Haiyan Li</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100076</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 11, 2020</study_first_submitted>
  <study_first_submitted_qc>March 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2020</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Subject</keyword>
  <keyword>PK Study</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Safety Evaluation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

